13.05.2022 - FREMONT, Calif., May 13, 2022 (GLOBE NEWSWIRE) - Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2022. All share and per share information .
Zosano Pharma (ZSAN) Reports Q1 Net Loss of $33 4M streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
The FDA amended emergency authorization of Johnson & Johnson’s Covid-19 vaccine. In other regulatory news this past week, drug approvals include a cancer drug that converted its accelerated regulatory approval to a full regulatory nod, while several companies dealt with rejections or clinical trial setbacks.
StockNews.com initiated coverage on shares of Zosano Pharma (NASDAQ:ZSAN – Get Rating) in a research note published on Monday morning. The firm issued a sell rating on the biotechnology company’s stock. Separately, BTIG Research downgraded shares of Zosano Pharma from a buy rating to a neutral rating in a research report on Wednesday, February 23rd. […]